RecruitingNCT05004987
Escitalopram or placebo for depression and Alzheimer’s disease risk markers
About this title
Read the official source — NCT05004987Medication studyAges 60+United States
Understand this study
Who could participate?
Listed age limits: from 60 years.
- Listed locations
- New York and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 4, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 60 Years
- Official registry ID
- NCT05004987
- Official title
Show the full official title
Depression Treatment and Aβ Dynamics: A Study of Alzheimer's Disease Risk (ABD Study)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New York · Orangeburg
Questions about this study
Who is behind this study?
The study sponsor is NYU Langone Health.
Does this study involve medication?
Yes. The study involves medication, including Escitalopram Oxalate and Placebo.
Who can participate?
Listed age limits: from 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
